Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Schering_AG
|
| gptkbp:acquisition |
gptkb:Lupin_Pharmaceuticals
Liva Healthcare |
| gptkbp:awards |
Best Employer Award 2020
Best Corporate Social Responsibility Award 2021 Pharma Innovation Award 2019 |
| gptkbp:ceo |
Sharvil Patel
|
| gptkbp:clinical_trial |
conducts numerous clinical trials
|
| gptkbp:employees |
over 25,000
|
| gptkbp:founded |
gptkb:1952
|
| gptkbp:founder |
gptkb:Zydus_Cadila
|
| gptkbp:has_expansion |
R& D center in Hyderabad
global presence in Asia global presence in Europe global presence in the US new manufacturing facility in Gujarat |
| gptkbp:headquarters |
gptkb:Ahmedabad,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cadila Healthcare
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market_cap |
approximately $5 billion (2021)
|
| gptkbp:operates_in |
more than 100 countries
|
| gptkbp:partnership |
GSK for vaccines
Sanofi for vaccine research Astra Zeneca for vaccine development Bharat Biotech for COVID-19 vaccine Boehringer Ingelheim for biosimilars Novartis for research collaboration Pfizer for drug development |
| gptkbp:philanthropy |
Zydus Foundation
|
| gptkbp:products |
generic drugs
vaccines biologics over-the-counter medications |
| gptkbp:regulatory_compliance |
FDA approved
EMA approved WHO prequalification |
| gptkbp:research_focus |
gptkb:Company
oncology autoimmune diseases cardiovascular diseases infectious diseases |
| gptkbp:revenue |
$1.5 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Zydus_Cadila
|
| gptkbp:sustainability_initiatives |
education initiatives
community health programs women empowerment programs skill development programs environmental responsibility programs |
| gptkbp:website |
www.zyduscadila.com
|